Across TCGA pan-cancer cohorts, OR2B3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated OR2B3 data layer compared with 9 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher OR2B3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR2B3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

BLCA, UCEC, and LGG are the cancer types where OR2B3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.120	0.720	<.001	48	view →
UCEC	DFS	Median	All	1.000	0.626	.012	26	view →
LGG	OS	Median	All	0.214	0.812	<.001	18	view →
COAD	OS	Median	All	0.168	0.806	.002	12	view →
SKCM	DFS	Median	IV	1.000	0.201	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: OR2B3 tumor-vs-normal RNA expression · all OR2B3 data types